Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 11NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 139Vincristine 105Rituximab 100Doxorubicin 87Etoposide 79Prednisone 69Cytarabine 67Filgrastim 63Specimen Handling 62Methotrexate 60Biopsy 60Magnetic Resonance Spectroscopy 51fludarabine phosphate 50Dexamethasone 47Radiotherapy 43Peripheral Blood Stem Cell Transplantation 35Leucovorin 35Bortezomib 32Prednisolone 28Mercaptopurine 27merphos 24Ifosfamide 24Asparaginase 24Daunorubicin 23Lenalidomide 22ibrutinib 21fludarabine 21Calcium Dobesilate 21pegaspargase 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × carmustine, poliferprosan 20 drug combination × Lymphoid × Clear all
NCT00961220 2018-05-22

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 6 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡